vs

Side-by-side financial comparison of SEABOARD CORP (SEB) and Vertex Pharmaceuticals (VRTX). Click either name above to swap in a different company.

Vertex Pharmaceuticals is the larger business by last-quarter revenue ($3.2B vs $2.4B, roughly 1.3× SEABOARD CORP). Vertex Pharmaceuticals runs the higher net margin — 37.3% vs 10.6%, a 26.8% gap on every dollar of revenue. On growth, Vertex Pharmaceuticals posted the faster year-over-year revenue change (9.5% vs -2.9%). Vertex Pharmaceuticals produced more free cash flow last quarter ($348.6M vs $53.0M). Over the past eight quarters, Vertex Pharmaceuticals's revenue compounded faster (8.9% CAGR vs 4.9%).

Seaboard Corporation is a diverse multinational agribusiness and transportation conglomerate with integrated operations in several industries. In the United States, the company mainly engages in pork production and processing and ocean transportation. Internationally, Seaboard is primarily engaged in commodity merchandising, grain processing, sugar production and electrical power generation. The parent company, Seaboard Corporation is based in the Kansas City suburb of Merriam, Kansas. Its su...

Vertex Pharmaceuticals Incorporated is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry. It maintains headquarters in Boston, Massachusetts, and three research facilities, in San Diego, California, and Milton Park, Oxfordshire, England.

SEB vs VRTX — Head-to-Head

Bigger by revenue
VRTX
VRTX
1.3× larger
VRTX
$3.2B
$2.4B
SEB
Growing faster (revenue YoY)
VRTX
VRTX
+12.4% gap
VRTX
9.5%
-2.9%
SEB
Higher net margin
VRTX
VRTX
26.8% more per $
VRTX
37.3%
10.6%
SEB
More free cash flow
VRTX
VRTX
$295.6M more FCF
VRTX
$348.6M
$53.0M
SEB
Faster 2-yr revenue CAGR
VRTX
VRTX
Annualised
VRTX
8.9%
4.9%
SEB

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
SEB
SEB
VRTX
VRTX
Revenue
$2.4B
$3.2B
Net Profit
$255.0M
$1.2B
Gross Margin
7.9%
85.4%
Operating Margin
2.7%
37.8%
Net Margin
10.6%
37.3%
Revenue YoY
-2.9%
9.5%
Net Profit YoY
63.5%
30.5%
EPS (diluted)
$262.58
$4.64

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
SEB
SEB
VRTX
VRTX
Q4 25
$2.4B
$3.2B
Q3 25
$2.5B
$3.1B
Q2 25
$2.5B
$3.0B
Q1 25
$2.3B
$2.8B
Q4 24
$2.5B
$2.9B
Q3 24
$2.2B
$2.8B
Q2 24
$2.2B
$2.6B
Q1 24
$2.2B
$2.7B
Net Profit
SEB
SEB
VRTX
VRTX
Q4 25
$255.0M
$1.2B
Q3 25
$110.0M
$1.1B
Q2 25
$104.0M
$1.0B
Q1 25
$32.0M
$646.3M
Q4 24
$156.0M
$913.0M
Q3 24
$-149.0M
$1.0B
Q2 24
$61.0M
$-3.6B
Q1 24
$22.0M
$1.1B
Gross Margin
SEB
SEB
VRTX
VRTX
Q4 25
7.9%
85.4%
Q3 25
7.8%
86.5%
Q2 25
6.5%
86.3%
Q1 25
6.1%
86.9%
Q4 24
9.0%
85.5%
Q3 24
6.2%
85.8%
Q2 24
5.8%
85.9%
Q1 24
4.0%
87.3%
Operating Margin
SEB
SEB
VRTX
VRTX
Q4 25
2.7%
37.8%
Q3 25
3.3%
38.6%
Q2 25
2.1%
38.8%
Q1 25
1.6%
22.7%
Q4 24
4.6%
35.2%
Q3 24
1.4%
40.3%
Q2 24
1.4%
-132.9%
Q1 24
-0.9%
42.4%
Net Margin
SEB
SEB
VRTX
VRTX
Q4 25
10.6%
37.3%
Q3 25
4.3%
35.2%
Q2 25
4.2%
34.8%
Q1 25
1.4%
23.3%
Q4 24
6.3%
31.4%
Q3 24
-6.7%
37.7%
Q2 24
2.8%
-135.8%
Q1 24
1.0%
40.9%
EPS (diluted)
SEB
SEB
VRTX
VRTX
Q4 25
$262.58
$4.64
Q3 25
$113.71
$4.20
Q2 25
$105.22
$3.99
Q1 25
$32.95
$2.49
Q4 24
$158.58
$3.62
Q3 24
$-153.44
$4.01
Q2 24
$62.82
$-13.92
Q1 24
$22.66
$4.21

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
SEB
SEB
VRTX
VRTX
Cash + ST InvestmentsLiquidity on hand
$1.2B
$6.6B
Total DebtLower is stronger
Stockholders' EquityBook value
$5.2B
$18.7B
Total Assets
$8.2B
$25.6B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
SEB
SEB
VRTX
VRTX
Q4 25
$1.2B
$6.6B
Q3 25
$1.2B
$6.3B
Q2 25
$1.1B
$6.4B
Q1 25
$1.1B
$6.2B
Q4 24
$1.2B
$6.1B
Q3 24
$1.2B
$6.5B
Q2 24
$1.2B
$5.8B
Q1 24
$1.2B
$10.2B
Stockholders' Equity
SEB
SEB
VRTX
VRTX
Q4 25
$5.2B
$18.7B
Q3 25
$5.0B
$17.3B
Q2 25
$4.8B
$17.2B
Q1 25
$4.7B
$16.5B
Q4 24
$4.7B
$16.4B
Q3 24
$4.5B
$15.6B
Q2 24
$4.7B
$14.8B
Q1 24
$4.6B
$18.5B
Total Assets
SEB
SEB
VRTX
VRTX
Q4 25
$8.2B
$25.6B
Q3 25
$8.0B
$24.9B
Q2 25
$7.9B
$24.0B
Q1 25
$7.6B
$22.9B
Q4 24
$7.7B
$22.5B
Q3 24
$7.5B
$22.2B
Q2 24
$7.7B
$20.1B
Q1 24
$7.6B
$23.9B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
SEB
SEB
VRTX
VRTX
Operating Cash FlowLast quarter
$188.0M
$498.0M
Free Cash FlowOCF − Capex
$53.0M
$348.6M
FCF MarginFCF / Revenue
2.2%
10.9%
Capex IntensityCapex / Revenue
5.6%
4.7%
Cash ConversionOCF / Net Profit
0.74×
0.42×
TTM Free Cash FlowTrailing 4 quarters
$6.0M
$3.2B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
SEB
SEB
VRTX
VRTX
Q4 25
$188.0M
$498.0M
Q3 25
$319.0M
$1.2B
Q2 25
$81.0M
$1.1B
Q1 25
$-20.0M
$818.9M
Q4 24
$300.0M
$584.6M
Q3 24
$194.0M
$1.4B
Q2 24
$6.0M
$-3.8B
Q1 24
$19.0M
$1.3B
Free Cash Flow
SEB
SEB
VRTX
VRTX
Q4 25
$53.0M
$348.6M
Q3 25
$152.0M
$1.1B
Q2 25
$-70.0M
$927.4M
Q1 25
$-129.0M
$778.2M
Q4 24
$162.0M
$492.0M
Q3 24
$58.0M
$1.3B
Q2 24
$-127.0M
$-3.8B
Q1 24
$-85.0M
$1.2B
FCF Margin
SEB
SEB
VRTX
VRTX
Q4 25
2.2%
10.9%
Q3 25
6.0%
37.0%
Q2 25
-2.8%
31.3%
Q1 25
-5.6%
28.1%
Q4 24
6.5%
16.9%
Q3 24
2.6%
47.0%
Q2 24
-5.7%
-144.5%
Q1 24
-3.9%
46.0%
Capex Intensity
SEB
SEB
VRTX
VRTX
Q4 25
5.6%
4.7%
Q3 25
6.6%
3.3%
Q2 25
6.1%
4.9%
Q1 25
4.7%
1.5%
Q4 24
5.6%
3.2%
Q3 24
6.1%
2.4%
Q2 24
6.0%
2.6%
Q1 24
4.7%
2.5%
Cash Conversion
SEB
SEB
VRTX
VRTX
Q4 25
0.74×
0.42×
Q3 25
2.90×
1.15×
Q2 25
0.78×
1.04×
Q1 25
-0.63×
1.27×
Q4 24
1.92×
0.64×
Q3 24
1.31×
Q2 24
0.10×
Q1 24
0.86×
1.19×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

SEB
SEB

Commodity Trading And Milling$1.3B52%
Pork Segment$469.0M19%
Marine$444.0M18%
Other$108.0M4%
Energy Service$56.0M2%
Product And Service Other Services$15.0M1%
Transportation$6.0M0%

VRTX
VRTX

TRIKAFTAKAFTRIO$2.6B81%
ALYFTREK$380.1M12%
Manufactured Product Other$237.4M7%

Related Comparisons